ClinicalTrials.gg
CompletedNCT01040637Updated May 22, 2026

A Multiple Dose Study of TD-1211 in Healthy Volunteers and Patients With Opioid-Induced Constipation

A Phase 1/2 interventional study of TD-1211 and TD-1211 in Healthy and Opioid-induced Constipation, sponsored by Glycyx Therapeutics. Completed at 3 sites in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-22.

Sponsored by Glycyx Therapeutics · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
102
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 43 studies in Opioid-Induced Constipation with a site in United States — 1 open to participants now, 2 under way, none of them phase 3. Opioid-Induced Constipation · United States.

Enrollment
26th of 40
102 · median 227
Started
2010
with 4 others
Phase 1/2
Only one
of the 43
Registered
15th of 43
by date
Lead sponsor
6 of 43
Glycyx Therapeutics

Among the 43 studies in Opioid-Induced Constipation with a site in United States, this one is the 26th largest by enrollment of the 40 interventional ones that give a count, is one of 5 that started in 2010, is the only one in phase 1/2, and was the 15th registered.

Opioid-Induced Constipation

87 studies on the registry are indexed under Opioid-Induced Constipation; 6 are open to participants now.

Browse Opioid-Induced Constipation studies →

Open to participants now

1 of the 43 studies in Opioid-Induced Constipation with a site in United States is open now. Recruiting first, the newest first:

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 5 Opioid-Induced Constipation studies recruiting now, 3 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Opioid-Induced Constipation with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of TD-1211 in healthy subjects and activity in subjects with opioid-induced constipation (OIC).

03

Conditions studied

  • Healthy
  • Opioid-induced Constipation

Keywords

  • Healthy subjects
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females between 18 and 65 years of age, inclusive
  • Healthy subjects and subjects with documented OIC on stable opioid regimen
  • Willingness to stop all laxatives throughout the OIC screening and treatment period

Exclusion criteria

Exclusion Criteria:

  • Any finding in healthy subjects
  • Have participated in another clinical trial of an drug 30 days prior to screening
  • History of chronic constipation prior to opioid therapy in OIC subjects
  • Active medical disorders associated with diarrhea or intermittent loose stools in OIC subjects
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
102 participants (actual)

Study arms

  • Experimental
    TD-1211 dose level 1

    Ascending doses

    Drug: TD-1211

  • Experimental
    TD-1211 dose level 2

    Ascending doses

    Drug: TD-1211

  • Experimental
    TD-1211 dose level 3

    Ascending doses

    Drug: TD-1211

  • Experimental
    TD-1211 dose level 4

    Ascending doses

    Drug: TD-1211

  • Experimental
    TD-1211 OIC dose level 1

    Ascending doses

    Drug: TD-1211

  • Experimental
    TD-1211 OIC dose level 2

    Ascending doses

    Drug: TD-1211

  • Experimental
    TD-1211 OIC dose level 3

    Ascending doses

    Drug: TD-1211

  • Experimental
    TD-1211 OIC dose level 4

    Ascending doses

    Drug: TD-1211

  • Experimental
    TD-1211 OIC dose level 5

    Ascending doses

    Drug: TD-1211

  • Placebo comparator
    Placebo

    Ascending doses

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Safety and tolerability in healthy subjects and activity in subjects with opioid-induced constipation

    Time frame: Daily pre and post dose assessments throughout the duration of the study period

Secondary outcomes

  1. Evaluation of the multiple dose pharmacokinetics of TD-1211 following oral administration

    Time frame: Daily pre and post dose assessments throughout the duration of the study period

07

Study locations

3 sites
  • Clinical Research Unit
    Pasadena, California 91105, United States
  • Clinical Research Unit
    San Antonio, Texas 78209, United States
  • Clinical Research Unit
    Salt Lake City, Utah 84106, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2010, a primary completion of Oct 2010 and a completion of Oct 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 22, 2009
First posted
Dec 29, 2009
Start
Jan 2010
Primary completionActual
Oct 2010
CompletionActual
Oct 2010
Results delay requested
Feb 8, 2013
Last update
May 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01040637
Lead sponsor
Glycyx Therapeutics
Responsible party
Sponsor
First posted
Dec 29, 2009
Start date
Jan 2010
Primary completion
Oct 2010
Completion
Oct 2010
Last update
May 22, 2026

Study contacts

Medical Monitor
study director · Theravance Biopharma

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Axelopran

Start the discussion